Yakob Liawatidewi - Aug 28, 2023 Form 4 Insider Report for Amphastar Pharmaceuticals, Inc. (AMPH)

Role
EVP Corp Admin Center, Director
Signature
/s/ Eva Wen, by power of attorney
Stock symbol
AMPH
Transactions as of
Aug 28, 2023
Transactions value $
-$1,102,900
Form type
4
Date filed
8/29/2023, 06:54 PM
Previous filing
Jun 6, 2023
Next filing
Mar 6, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AMPH Common Stock Options Exercise $56.3K +3.32K +4.76% $16.96 73K Aug 28, 2023 Direct
transaction AMPH Common Stock Options Exercise $111K +5.5K +7.53% $20.23 78.5K Aug 28, 2023 Direct
transaction AMPH Common Stock Options Exercise $261K +20K +25.48% $13.03* 98.5K Aug 28, 2023 Direct
transaction AMPH Common Stock Sale -$1.53M -28.8K -29.26% $53.13 69.7K Aug 28, 2023 Direct F1, F2
holding AMPH Common Stock 2.46K Aug 28, 2023 See footnote F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AMPH Employee Stock Option (right to buy) Options Exercise $0 -3.32K -100% $0.00* 0 Aug 28, 2023 Common Stock 3.32K $16.96 Direct F4
transaction AMPH Employee Stock Option (right to buy) Options Exercise $0 -5.5K -100% $0.00* 0 Aug 28, 2023 Common Stock 5.5K $20.23 Direct F4
transaction AMPH Employee Stock Option (right to buy) Options Exercise $0 -20K -55.29% $0.00 16.2K Aug 28, 2023 Common Stock 20K $13.03 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 19, 2023.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.87 to $53.74, inclusive.The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
F3 The reported shares are held of record by the Yakob and Sunmoon Trust dated July 25, 2013 for which the reporting person serves as a trustee.
F4 Shares subject to the option are fully vested and immediately exercisable.
F5 Shares subject to the option vest in four equal annual installments beginning on March 16, 2021.